Nkx-2.2 Activators
Nkx-2.2 Activators comprise a diverse array of compounds intricately designed to modulate specific signaling pathways associated with Nkx-2.2 activity. These transcriptional activators play critical roles in various developmental processes, including pancreatic and neural development. A83-01, a TGF-β signaling activator, inhibits type I receptors ALK4, ALK5, and ALK7, thereby enhancing TGF-β pathway activity crucial for Nkx-2.2 involvement in pancreatic development. A83-01's specific modulation of the TGF-β pathway enables the activation of Nkx-2.2 by promoting the downstream signaling cascade. CHIR99021, a Wnt signaling activator, operates by inhibiting GSK-3β, leading to increased stability of β-catenin. This stabilization activates the Wnt pathway, influencing Nkx-2.2 in pancreatic development. SAG, a Hedgehog (Hh) signaling activator, promotes Smoothened (SMO) activity, directly impacting the Hh pathway crucial for Nkx-2.2 in neural tube patterning. These activators exemplify the precise modulation of cellular pathways to orchestrate the activation of Nkx-2.2 in distinct developmental contexts.
BIO, another Wnt signaling activator, inhibits GSK-3, leading to stabilized β-catenin and increased Wnt pathway activity influencing Nkx-2.2. Purmorphamine, a Hedgehog (Hh) signaling activator, enhances Smoothened (SMO) activity, directly impacting the Hh pathway crucial for Nkx-2.2 in neural tube patterning. In summary, Nkx-2.2 Activators encompass a collection of compounds that intricately influence specific cellular pathways associated with Nkx-2.2. Their targeted modulation provides valuable insights into the regulatory networks governing Nkx-2.2 activation during diverse developmental processes. Understanding the detailed biochemical and cellular mechanisms through which these activators act enables a nuanced comprehension of Nkx-2.2 regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A83-01 activates TGF-β signaling by inhibiting the type I receptors ALK4, ALK5, and ALK7. Nkx-2.2 is implicated in pancreatic development influenced by TGF-β signaling, and A83-01 can activate Nkx-2.2 by enhancing TGF-β pathway activity through its inhibitory action on the type I receptors. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
GSK-3 Inhibitor XVI (CHIR99021) activates Wnt signaling by inhibiting GSK-3β. Nkx-2.2 is involved in pancreatic development influenced by Wnt signaling, and CHIR99021 can activate Nkx-2.2 by stabilizing β-catenin through GSK-3β inhibition, leading to increased Wnt pathway activity. | ||||||
SAG | 912545-86-9 | sc-212905 sc-212905A | 1 mg 5 mg | $166.00 $421.00 | 27 | |
SAG activates Hedgehog (Hh) signaling by promoting Smoothened (SMO) activity. Nkx-2.2 is part of neural tube patterning influenced by Hh signaling, and SAG can activate Nkx-2.2 by enhancing Hh pathway activity through direct modulation of SMO. | ||||||
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
GSK-3 Inhibitor IX (BIO) activates Wnt signaling by inhibiting GSK-3. Nkx-2.2 is involved in pancreatic development influenced by Wnt signaling, and BIO can activate Nkx-2.2 by stabilizing β-catenin through GSK-3 inhibition, leading to increased Wnt pathway activity. | ||||||
Purmorphamine | 483367-10-8 | sc-202785 sc-202785A | 1 mg 5 mg | $57.00 $184.00 | 18 | |
Purmorphamine activates Hedgehog (Hh) signaling by promoting Smoothened (SMO) activity. Nkx-2.2 is part of neural tube patterning influenced by Hh signaling, and Purmorphamine can activate Nkx-2.2 by enhancing Hh pathway activity through direct modulation of SMO. | ||||||
GW788388 | 452342-67-5 | sc-363544 sc-363544A | 5 mg 25 mg | $95.00 $384.00 | ||
GW788388 activates TGF-β signaling by inhibiting the type I receptors ALK4, ALK5, and ALK7. Nkx-2.2 is implicated in pancreatic development influenced by TGF-β signaling, and GW788388 can activate Nkx-2.2 by enhancing TGF-β pathway activity through its inhibitory action on the type I receptors. | ||||||
GSK343 | 1346704-33-3 | sc-397025 sc-397025A | 5 mg 25 mg | $151.00 $461.00 | 1 | |
GSK343 activates Wnt signaling by inhibiting the histone methyltransferase EZH2. Nkx-2.2 is involved in pancreatic development influenced by Wnt signaling, and GSK343 can activate Nkx-2.2 by promoting the expression of Wnt target genes through EZH2 inhibition, leading to increased Wnt pathway activity. | ||||||
LDN-214117 | 1627503-67-6 | sc-507451 | 5 mg | $165.00 | ||
LDN-214117 activates TGF-β signaling by inhibiting the type I receptors ALK4, ALK5, and ALK7. Nkx-2.2 is implicated in pancreatic development influenced by TGF-β signaling, and LDN-214117 can activate Nkx-2.2 by enhancing TGF-β pathway activity through its inhibitory action on the type I receptors. | ||||||